Symbols / BCRX Stock $9.24 +2.73% BioCryst Pharmaceuticals, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NMS
BCRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. Charles K. Gayer
Exch · Country NMS · United States
Market Cap 2.35B
Enterprise Value 2.46B
Income 263.86M
Sales 874.84M
FCF (ttm) 256.42M
Book/sh -0.56
Cash/sh 1.09
Employees 435
Insider 10d —
IPO Mar 04, 1994
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 7.63
Forward P/E 11.51
PEG 9.39
P/S 2.68
P/B -16.52
P/C —
EV/EBITDA 7.00
EV/Sales 2.81
Quick Ratio 1.95
Current Ratio 2.06
Debt/Eq —
LT Debt/Eq —
EPS (ttm) 1.21
EPS next Y 0.80
EPS Growth —
Revenue Growth 209.10%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-06
Earnings (prior) 2026-02-26
ROA 43.21%
ROE —
ROIC —
Gross Margin 79.06%
Oper. Margin 65.60%
Profit Margin 30.16%
Shs Outstand 254.11M
Shs Float 218.18M
Insider Own 1.15%
Instit Own 89.63%
Short Float 15.28%
Short Ratio 5.68
Short Interest 38.53M
52W High 11.31
vs 52W High -18.35%
52W Low 6.00
vs 52W Low 53.92%
Beta 0.69
Impl. Vol. 71.19%
Rel Volume 0.34
Avg Volume 5.21M
Volume 1.79M
Target (mean) $21.40
Tgt Median $20.00
Tgt Low $14.00
Tgt High $32.00
# Analysts 10
Recom Strong_buy
Prev Close $8.99
Price $9.23
Change 2.73%
About

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$21.40
Mean price target
2. Current target
$9.24
Latest analyst target
3. DCF / Fair value
$18.16
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$9.24
Low
$14.00
High
$32.00
Mean
$21.40

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-01-30 main RBC Capital Outperform → Outperform $13
2025-12-15 main HC Wainwright & Co. Buy → Buy $32
2025-11-05 main Citizens Market Outperform → Market Outperform $25
2025-11-04 main Barclays Equal-Weight → Equal-Weight $9
2025-11-04 main Needham Buy → Buy $18
2025-10-15 main Cantor Fitzgerald Overweight → Overweight $26
2025-10-15 main JMP Securities Market Outperform → Market Outperform $27
2025-10-15 main Needham Buy → Buy $20
2025-08-04 main Needham Buy → Buy $17
2025-07-01 main B of A Securities Buy → Buy $15
2025-06-30 reit RBC Capital Outperform → Outperform $13
2025-06-30 main Wedbush Outperform → Outperform $18
2025-06-27 reit Needham Buy → Buy $17
2025-06-25 reit Needham Buy → Buy $17
2025-05-07 main Barclays Equal-Weight → Equal-Weight $11
2025-05-06 reit RBC Capital Outperform → Outperform $13
2025-05-06 main JP Morgan Overweight → Overweight $13
2025-05-06 reit HC Wainwright & Co. Buy → Buy $30
2025-05-06 main Needham Buy → Buy $17
2025-04-29 init Cantor Fitzgerald — → Overweight $20
News
RSS: Latest BCRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-06 MENON SANDEEP Officer — 205,150 $0.00 $0
2026-03-20 HEGGIE THERESA Director — 49,933 $10.11 $504,823
2026-03-20 HEGGIE THERESA Director — 49,933 $6.30 $314,578
2026-03-16 BARNES ALANE P Officer — 150,000 $9.15 $1,372,500
2026-03-16 BARNES ALANE P Officer — 150,000 $5.51 $826,500
2026-03-02 STONEHOUSE JON P Director — 305,995 $3.22 $985,304
2026-02-27 FRANK STEVEN R Director — 1,285 $8.75 $11,244
2026-02-27 MILNE JILL C. PH.D. Director — 528 $8.75 $4,620
2026-02-27 MCKEE AMY E Director — 642 $8.75 $5,618
2026-02-27 STONEHOUSE JON P Director — 421 $8.75 $3,684
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
874.84
+94.10%
450.71
+36.00%
331.41
+22.37%
270.83
Operating Revenue
874.84
+94.10%
450.71
+36.00%
331.41
+22.37%
270.83
Cost Of Revenue
19.07
+55.47%
12.27
+173.80%
4.48
-32.04%
6.59
Reconciled Cost Of Revenue
19.07
+55.47%
12.27
+173.80%
4.48
-32.04%
6.59
Gross Profit
855.76
+95.18%
438.44
+34.11%
326.93
+23.73%
264.23
Operating Expense
514.77
+16.73%
440.99
+2.40%
430.64
+4.36%
412.67
Research And Development
166.13
-4.87%
174.64
-19.36%
216.57
-14.50%
253.30
Selling General And Administration
348.65
+30.90%
266.35
+24.42%
214.07
+34.32%
159.37
Total Expenses
533.85
+17.78%
453.25
+4.17%
435.12
+3.78%
419.26
Operating Income
340.99
+13508.93%
-2.54
+97.55%
-103.71
+30.13%
-148.44
Total Operating Income As Reported
340.99
+13508.93%
-2.54
+97.55%
-103.71
+30.13%
-148.44
EBITDA
347.65
+2614.33%
12.81
+111.01%
-116.33
+19.13%
-143.85
Normalized EBITDA
365.14
+2614.97%
13.45
+115.59%
-86.28
+39.19%
-141.87
Reconciled Depreciation
1.39
+11.48%
1.25
-24.71%
1.66
+15.17%
1.44
EBIT
346.26
+2894.84%
11.56
+109.80%
-117.99
+18.79%
-145.29
Total Unusual Items
-17.48
-2627.61%
-0.64
+97.87%
-30.06
-1415.78%
-1.98
Total Unusual Items Excluding Goodwill
-17.48
-2627.61%
-0.64
+97.87%
-30.06
-1415.78%
-1.98
Special Income Charges
-17.33
0.00
+100.00%
-29.02
0.00
Other Special Charges
17.33
—
29.02
—
Net Income
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Pretax Income
267.39
+407.51%
-86.95
+61.56%
-226.23
+7.43%
-244.38
Net Non Operating Interest Income Expense
-68.20
+18.58%
-83.77
+9.40%
-92.46
+1.60%
-93.97
Interest Expense Non Operating
78.87
-19.94%
98.52
-8.98%
108.24
+9.23%
99.09
Net Interest Income
-68.20
+18.58%
-83.77
+9.40%
-92.46
+1.60%
-93.97
Interest Expense
78.87
-19.94%
98.52
-8.98%
108.24
+9.23%
99.09
Interest Income Non Operating
10.67
-27.65%
14.75
-6.53%
15.78
+207.72%
5.13
Interest Income
10.67
-27.65%
14.75
-6.53%
15.78
+207.72%
5.13
Other Income Expense
-5.39
-741.50%
-0.64
+97.87%
-30.06
-1415.78%
-1.98
Other Non Operating Income Expenses
12.09
—
—
—
Gain On Sale Of Security
-0.15
+76.29%
-0.64
+38.31%
-1.04
+47.60%
-1.98
Tax Provision
3.53
+83.19%
1.93
+521.61%
0.31
-88.66%
2.73
Tax Rate For Calcs
0.00
-95.24%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.17
-29.89%
-0.13
+97.87%
-6.31
-1415.78%
-0.42
Net Income Including Noncontrolling Interests
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Net Income From Continuing Operation Net Minority Interest
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Net Income From Continuing And Discontinued Operation
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Net Income Continuous Operations
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Normalized Income
281.17
+418.16%
-88.37
+56.42%
-202.79
+17.41%
-245.55
Net Income Common Stockholders
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Diluted EPS
1.21
+381.40%
-0.43
+63.56%
-1.18
+11.28%
-1.33
Basic EPS
1.26
+393.02%
-0.43
+63.56%
-1.18
+11.28%
-1.33
Basic Average Shares
209.89
+1.55%
206.70
+7.54%
192.20
+3.38%
185.91
Diluted Average Shares
218.58
+5.75%
206.70
+7.54%
192.20
+3.38%
185.91
Diluted NI Availto Com Stockholders
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Line Item Trend 2023-12-31
Total Assets
516.96
Current Assets
495.97
Cash Cash Equivalents And Short Term Investments
388.99
Cash And Cash Equivalents
110.64
Other Short Term Investments
278.34
Receivables
56.95
Accounts Receivable
56.95
Inventory
28.68
Raw Materials
6.45
Work In Process
17.59
Finished Goods
6.24
Prepaid Assets
—
Restricted Cash
1.80
Other Current Assets
19.54
Total Non Current Assets
20.99
Net PPE
20.91
Gross PPE
32.12
Accumulated Depreciation
-11.21
Properties
0.00
Machinery Furniture Equipment
3.35
Construction In Progress
0.00
Other Properties
18.56
Leases
10.21
Investments And Advances
0.00
Other Non Current Assets
0.08
Total Liabilities Net Minority Interest
972.49
Current Liabilities
149.99
Payables And Accrued Expenses
60.75
Payables
39.42
Accounts Payable
20.89
Other Payable
18.52
Current Accrued Expenses
21.33
Pensionand Other Post Retirement Benefit Plans Current
36.52
Total Tax Payable
—
Current Debt And Capital Lease Obligation
2.65
Current Capital Lease Obligation
2.65
Current Deferred Liabilities
0.00
Current Deferred Revenue
0.00
Other Current Liabilities
23.57
Total Non Current Liabilities Net Minority Interest
822.50
Long Term Debt And Capital Lease Obligation
822.50
Long Term Debt
811.26
Long Term Capital Lease Obligation
11.23
Stockholders Equity
-455.53
Common Stock Equity
-455.53
Capital Stock
2.06
Common Stock
2.06
Preferred Stock
0.00
Share Issued
205.77
Ordinary Shares Number
205.77
Treasury Shares Number
0.00
Additional Paid In Capital
1,222.24
Retained Earnings
-1,681.16
Gains Losses Not Affecting Retained Earnings
1.34
Other Equity Adjustments
1.34
Total Equity Gross Minority Interest
-455.53
Total Capitalization
355.74
Working Capital
345.98
Invested Capital
355.74
Total Debt
825.15
Net Debt
700.62
Capital Lease Obligations
13.88
Net Tangible Assets
-455.53
Tangible Book Value
-455.53
Available For Sale Securities
—
Current Provisions
26.51
Inventories Adjustments Allowances
-1.60
Investmentin Financial Assets
—
Other Inventories
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
347.37
+767.76%
-52.02
+45.32%
-95.14
+41.22%
-161.85
Cash Flow From Continuing Operating Activities
347.37
+767.76%
-52.02
+45.32%
-95.14
+41.22%
-161.85
Net Income From Continuing Operations
263.86
+396.87%
-88.88
+60.77%
-226.54
+8.33%
-247.12
Depreciation Amortization Depletion
1.39
+11.48%
1.25
-24.71%
1.66
+15.17%
1.44
Depreciation
1.39
+11.48%
1.25
-24.71%
1.66
+15.17%
1.44
Depreciation And Amortization
1.39
+11.48%
1.25
-24.71%
1.66
+15.17%
1.44
Other Non Cash Items
30.85
-54.37%
67.61
-21.21%
85.80
-13.26%
98.92
Stock Based Compensation
80.75
+23.45%
65.41
+17.62%
55.62
+24.42%
44.70
Asset Impairment Charge
0.98
-27.04%
1.35
-31.47%
1.97
+111.37%
0.93
Operating Gains Losses
30.76
—
29.02
—
Gain Loss On Investment Securities
-0.55
—
—
—
Change In Working Capital
-56.90
+34.81%
-87.28
-169.38%
-32.40
+45.03%
-58.95
Change In Receivables
-36.81
-62.16%
-22.70
-272.40%
-6.09
+71.61%
-21.47
Change In Inventory
-1.64
+60.64%
-4.16
-187.17%
-1.45
+88.33%
-12.42
Change In Prepaid Assets
-7.83
-499.54%
1.96
+128.72%
-6.82
-164.03%
-2.58
Change In Payables And Accrued Expense
57.80
+291.19%
14.78
+17.92%
12.53
+156.04%
-22.36
Change In Accrued Expense
—
—
0.00
0.00
Change In Payable
57.80
+291.19%
14.78
+17.92%
12.53
+156.04%
-22.36
Change In Account Payable
57.80
+291.19%
14.78
+17.92%
12.53
+156.04%
-22.36
Change In Other Working Capital
—
—
-1.23
-1028.44%
-0.11
Change In Other Current Liabilities
-68.43
+11.31%
-77.16
-163.00%
-29.34
—
Investing Cash Flow
-13.69
-126.04%
52.59
+140.00%
-131.50
-2.54%
-128.24
Cash Flow From Continuing Investing Activities
-13.69
-126.04%
52.59
+140.00%
-131.50
-2.54%
-128.24
Net PPE Purchase And Sale
-2.47
-119.57%
-1.12
+48.15%
-2.17
-60.47%
-1.35
Purchase Of PPE
-2.47
-119.57%
-1.12
+48.15%
-2.17
-60.47%
-1.35
Capital Expenditure
-2.47
-119.57%
-1.12
+48.15%
-2.17
-60.47%
-1.35
Net Investment Purchase And Sale
-5.59
-110.41%
53.72
+141.53%
-129.33
-1.93%
-126.89
Purchase Of Investment
-262.24
+1.70%
-266.76
+48.14%
-514.41
-110.58%
-244.28
Sale Of Investment
256.65
-19.92%
320.48
-16.78%
385.08
+228.02%
117.40
Net Business Purchase And Sale
-6.18
0.00
0.00
—
Purchase Of Business
-6.18
0.00
0.00
—
Gain Loss On Sale Of Business
-3.57
0.00
0.00
—
Net Other Investing Changes
0.55
—
—
—
Financing Cash Flow
-349.93
-5974.14%
-5.76
-117.73%
32.48
-63.10%
88.03
Cash Flow From Continuing Financing Activities
-349.93
-5974.14%
-5.76
-117.73%
32.48
-63.10%
88.03
Net Issuance Payments Of Debt
-301.99
-17622.36%
-1.70
-102.92%
58.38
-20.10%
73.07
Issuance Of Debt
0.00
0.00
-100.00%
300.00
+310.55%
73.07
Repayment Of Debt
-301.99
-17622.36%
-1.70
+99.29%
-241.62
0.00
Long Term Debt Issuance
0.00
0.00
-100.00%
300.00
+310.55%
73.07
Long Term Debt Payments
-301.99
-17622.36%
-1.70
+99.29%
-241.62
0.00
Net Long Term Debt Issuance
-301.99
-17622.36%
-1.70
-102.92%
58.38
-20.10%
73.07
Short Term Debt Issuance
—
—
—
73.07
Short Term Debt Payments
—
—
—
0.00
Net Short Term Debt Issuance
—
—
—
73.07
Net Common Stock Issuance
0.06
+73.53%
0.03
-90.06%
0.34
+80.00%
0.19
Proceeds From Stock Option Exercised
9.12
+164.66%
3.44
-58.71%
8.34
-43.52%
14.77
Net Other Financing Charges
-57.12
-658.01%
-7.54
+78.21%
-34.58
—
Changes In Cash
-16.26
-213.34%
-5.19
+97.33%
-194.15
+3.91%
-202.06
Effect Of Exchange Rate Changes
1.27
+235.68%
-0.94
-358.56%
0.36
-36.04%
0.57
Beginning Cash Position
106.32
-5.45%
112.45
-63.28%
306.24
-39.69%
507.73
End Cash Position
91.34
-14.09%
106.32
-5.45%
112.45
-63.28%
306.24
Free Cash Flow
344.90
+748.99%
-53.14
+45.39%
-97.31
+40.37%
-163.20
Interest Paid Supplemental Data
23.73
-21.88%
30.38
+37.24%
22.14
0.00
Income Tax Paid Supplemental Data
—
1.60
+11.79%
1.43
-59.51%
3.54
Amortization Of Securities
-4.33
+62.25%
-11.47
-11.79%
-10.26
-477.55%
-1.78
Change In Interest Payable
—
—
0.00
0.00
Common Stock Issuance
0.06
+73.53%
0.03
-90.06%
0.34
+80.00%
0.19
Earnings Losses From Equity Investments
17.55
0.00
0.00
—
Issuance Of Capital Stock
0.06
+73.53%
0.03
-90.06%
0.34
+80.00%
0.19
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category